{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:54:19Z","timestamp":1790470459376,"version":"4.1.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Coronavirus disease 2019 (COVID-19) has become a worldwide pandemic responsible for millions of deaths around the world. Hypertension has been identified as one of the most common comorbidities and risk factors for severity and adverse outcome in these patients. Recent investigations have raised the question whether hypertension represents a predictor of outcome in COVID-19 patients independently of other common comorbidities such as diabetes, obesity, other cardiovascular diseases, chronic kidney, liver, and pulmonary diseases. However, the impact of chronic and newly diagnosed hypertension in COVID-19 patients has been insufficiently investigated. The same is true for the relationship between blood pressure levels and outcomes in COVID-19 patients. It seems that the long discussion about the impact of angiotensin-converting enzyme inhibitors (ACEI) and blockers of angiotensin I receptors (ARB) on severity and outcome in COVID-19 is approaching an end because the large number of original studies and meta-analyses discarded the initial findings about higher prevalence of ACEI\/ARB use in patients with unfavorable outcomes. Nevertheless, there are many controversies in the relationship between hypertension and COVID-19. The aim of this review article is to provide a clinical overview of the currently available evidence regarding the predictive value of hypertension, the effect of blood pressure levels, the impact of previously known and newly diagnosed hypertension, and the effect of antihypertensive therapy on the severity and outcomes in COVID-19 patients.<\/jats:p>","DOI":"10.3389\/fcvm.2021.639222","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T03:18:12Z","timestamp":1613704692000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":48,"title":["Hypertension and COVID-19: Ongoing Controversies"],"prefix":"10.3389","volume":"8","author":[{"given":"Marijana","family":"Tadic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahrai","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Taddei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Mancia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Cuspidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019. Pneumonia in Wuhan, China","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Intern Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2002144","DOI":"10.1183\/13993003.02144-2020","article-title":"Characteristics and risk factors for COVID-19 diagnosis and adverse outcomes in Mexico: an analysis of 89,756 laboratory-confirmed COVID-19 cases","volume":"30","author":"Giannouchos","year":"2020","journal-title":"Eur Respir J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e23327","DOI":"10.1097\/MD.0000000000023327","article-title":"Clinical symptoms, comorbidities and complications in severe and non-severe patients with COVID-19: A systematic review and meta-analysis without cases duplication","volume":"99","author":"Wang","year":"2020","journal-title":"Medicine."},{"key":"B5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13098-020-00586-4","article-title":"Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis","volume":"12","author":"de","year":"2020","journal-title":"Diabetol Metab Syndr"},{"key":"B6","article-title":"Independent and combined effects of hypertension and diabetes on clinical outcomes in patients with COVID-19: a retrospective cohort study of Huoshen mountain hospital and Guanggu Fangcang Shelter Hospital","volume-title":"J Clin Hypertens.","author":"Sun","year":"2020"},{"key":"B7","doi-asserted-by":"publisher","first-page":"101226","DOI":"10.1016\/j.eujim.2020.101226","article-title":"Predictors of mortality in patients with COVID-19-a systematic review","volume":"40","author":"Mehraeen","year":"2020","journal-title":"Eur J Integr Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1001\/jamacardio.2020.1017","article-title":"Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)","volume":"5","author":"Guo","year":"2020","journal-title":"JAMA Cardiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1164\/rccm.202002-0445OC","article-title":"COVID-19 with different severities: a multicenter study of clinical features","volume":"201","author":"Feng","year":"2020","journal-title":"Am J Respir Crit Care Med."},{"key":"B10","article-title":"Effects of renin-angiotensin-aldosterone system (RAAS) inhibitors on disease severity and mortality in patients with COVID-19: a meta-analysis","volume-title":"J Med Virol.","author":"Zhang","year":"2020"},{"key":"B11","article-title":"Association between renin-angiotensin-aldosterone system inhibitor use and COVID-19 hospitalization and death: A 1,4 million patient nation-wide registry analysis","volume-title":"Eur J Heart Fail.","author":"Savarese","year":"2020"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e001353","DOI":"10.1136\/openhrt-2020-001353","article-title":"Renin-angiotensin-aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis","volume":"7","author":"Ssentongo","year":"2020","journal-title":"Open Heart."},{"key":"B13","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.26625","article-title":"The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: a systematic review and meta-analysis","volume-title":"J Med Virol.","author":"Wang","year":"2020"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.3390\/jcm9103136","article-title":"Association of hypertension with all-cause mortality among hospitalized patients with COVID-19","volume":"9","author":"Rodilla","year":"2020","journal-title":"J Clin Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1017\/S095026882000117X","article-title":"Association of hypertension with the severity and fatality of SARS-CoV-2 infection: a meta-analysis","volume":"148","author":"Zhang","year":"2020","journal-title":"Epidemiol Infect."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamainternmed.2020.3596","article-title":"Factors associated with death in critically ill patients with coronavirus disease 2019 in the US","volume":"180","author":"Gupta","year":"2020","journal-title":"JAMA Intern Med."},{"key":"B17","article-title":"Hypertension, medications, and risk of severe COVID-19: a Massachusetts community-based observational study","volume-title":"J Clin Hypertens.","author":"Bauer","year":"2020"},{"key":"B18","doi-asserted-by":"publisher","first-page":"bvaa102","DOI":"10.1210\/jendso\/bvaa102","article-title":"Prevalence of diabetes and hypertension and their associated risks for poor outcomes in Covid-19 patients","volume":"4","author":"Barrera","year":"2020","journal-title":"J Endocr Soc."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1001\/jamainternmed.2020.3539","article-title":"Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy","volume":"180","author":"Grasselli","year":"2020","journal-title":"JAMA Intern Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1002\/oby.22946","article-title":"The association of obesity, type 2 diabetes, and hypertension with severe coronavirus disease 2019 on Admission among Mexican patients","volume":"28","author":"Denova-Guti\u00e9rrez","year":"2020","journal-title":"Obesity."},{"key":"B21","doi-asserted-by":"publisher","first-page":"dc201444","DOI":"10.2337\/figshare.13034210","article-title":"Type 2 diabetes and COVID-19-related mortality in the critical care setting: a national cohort study in England, march-july (2020)","volume":"23","author":"Dennis","year":"2020","journal-title":"Diabetes Care."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/s41440-020-00541-w","article-title":"Blood pressure control and adverse outcomes of COVID-19 infection in patients with concomitant hypertension in Wuhan, China","volume":"43","author":"Ran","year":"2020","journal-title":"Hypertens Res."},{"key":"B23","doi-asserted-by":"crossref","DOI":"10.1111\/jch.14038","article-title":"Influence of blood pressure control and application of renin-angiotensin-aldosterone system inhibitors on the outcomes in COVID-19 patients with hypertension","volume-title":"J Clin Hypertens.","author":"Chen","year":"2020"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.jacc.2009.10.061","article-title":"Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis","volume":"55","author":"Vlachopoulos","year":"2010","journal-title":"J Am Coll Cardiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.atherosclerosis.2020.10.014","article-title":"Endothelial dysfunction in COVID-19: Current findings and therapeutic implications","volume":"314","author":"N\u00e4gele","year":"2020","journal-title":"Atherosclerosis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1080\/07853890.2020.1802059","article-title":"Hypertension is a risk factor for adverse outcomes in patients with coronavirus disease 2019: a cohort study","volume":"52","author":"Xiong","year":"2020","journal-title":"Ann Med."},{"key":"B27","doi-asserted-by":"crossref","DOI":"10.1111\/dom.14099","article-title":"Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19","volume-title":"Diabetes Obes Metab.","author":"Li","year":"2020"},{"key":"B28","doi-asserted-by":"publisher","first-page":"108374","DOI":"10.1016\/j.diabres.2020.108374","article-title":"Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration","volume":"168","author":"Fadini","year":"2020","journal-title":"Diabetes Res Clin Pract."},{"key":"B29","doi-asserted-by":"crossref","DOI":"10.1101\/2020.09.25.20201731","article-title":"Antihypertensive medications and COVID-19 diagnosis and mortality: population based case-control analysis in the United Kingdom","volume-title":"medRxiv [Preprint].","author":"Rezel-Potts","year":"2020"},{"key":"B30","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/ehjcvp\/pvaa058","article-title":"Antihypertensive drugs in COVID-19 infection","volume":"6","author":"Pinto-Sietsma","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1093\/eurheartj\/ehaa433","article-title":"Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study","volume":"41","author":"Gao","year":"2020","journal-title":"Eur Heart J."},{"key":"B32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jjcc.2020.10.015","article-title":"Lack of association of antihypertensive drugs with the risk and severity of COVID-19: a meta-analysis","volume-title":"J Cardiol.","author":"Ren","year":"2020"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","article-title":"Renin-angiotensin-aldosterone system blockers and the risk of Covid-19","volume":"382","author":"Mancia","year":"2020","journal-title":"N Engl J Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1097\/HJH.0000000000001961","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European society of cardiology and the European society of hypertension: the task force for the management of arterial hypertension of the European society of cardiology and the European society of hypertension","volume":"36","author":"Williams","year":"2018","journal-title":"J Hypertens."},{"key":"B35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40292-020-00380-3","article-title":"Renin-angiotensin system inhibition in cardiovascular patients at the time of COVID19: much ado for nothing? A statement of activity from the directors of the board and the scientific directors of the Italian society of hypertension","volume":"27","author":"Iaccarino","year":"2020","journal-title":"High Blood Press Cardiovasc Prev."},{"key":"B36","volume-title":"Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers","author":"De Simone","year":""},{"key":"B37","unstructured":""},{"key":"B38","doi-asserted-by":"publisher","first-page":"18909","DOI":"10.1038\/s41598-020-75848-2","article-title":"Explaining among-country variation in COVID-19 case fatality rate","volume":"10","author":"Sorci","year":"2020","journal-title":"Sci Rep."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.639222\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,25]],"date-time":"2021-04-25T07:04:04Z","timestamp":1619334244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.639222\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":38,"alternative-id":["10.3389\/fcvm.2021.639222"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.639222","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,17]]},"article-number":"639222"}}